Hexamethylmelamine enteric-coated tablets

This product is a pyrimidine antimetabolite antitumor drug. It mainly inhibits dihydrofolate reductase, interferes with folic acid metabolism, and selectively inhibits the synthesis of DNA, RNA and protein. It is a cell cycle-specific drug and has no cross-resistance with alkylating agents.

The main ingredient of this product is hexamethylenetetramine, and its chemical name is 2,4,6-tris(dimethylamino)-s-triazine.

This product is enteric-coated tablets, which appear white after removing the coating.

Used for combined chemotherapy of ovarian cancer, small cell lung cancer, malignant lymphoma, breast cancer, and bone marrow cancer.

Oral administration. 1. Single oral administration: 150-300 mg/m2 per day according to body surface area, divided into 3-4 times orally or taken before bedtime, 14-21 days as a course of treatment, rest for 2-3 weeks before the next course of treatment. 2. Combined oral administration: 100-200 mg/m2 per day according to body surface area, divided into 3 times orally or taken before bedtime, 14 days as a course of treatment, rest for 1 week.

1. Severe nausea and vomiting are dose-limiting toxicities. Myelosuppression is mild to moderate, with a prominent leukocytopenia, which usually occurs one week after treatment and reaches the lowest point in 3 to 4 weeks. 2. Central or peripheral nerve toxicity occurs after long-term use and is a dose-limiting toxicity that can be alleviated or disappear after stopping the drug for 4 to 5 months. 3. Occasionally, there may be hair loss, cystitis, rash, itching, weight loss, etc.

1. It is contraindicated for patients who are allergic to this product. 2. It is contraindicated for patients with severe bone marrow suppression and neurotoxicity.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Pregnant and lactating women should use this product with caution. Precautions for the elderly: Elderly patients over 65 years old should reduce the dosage as appropriate.

Combination with monoamine oxidase inhibitors and antidepressants can cause severe orthostatic hypotension and should be used with caution. Combination with metoclopramide can cause dystonia. Simultaneous use with vitamin B6 may reduce peripheral neurotoxicity.

Keep away from light and store in sealed container.

0.1 g

24 months

Tianjin Lisheng Pharmaceutical Co., Ltd.

• Founded in:

  1981-06-17

• Address:

  No. 16, Saida North 1st Road, Xiqing Economic Development Zone, Tianjin

• Tax NO.:

  91120000103069502J

• Registered Funds:

  257.942988 yuan

• Website:

  Log in to view

• Email:

  Log in to view